21. Pharmacological modulation of the adrenergic neurotransmission– levels and mechanisms.

Pharmacological modulation of the adrenergic neurotransmission

Pharmacological modulation of adrenergic neurotransmission involves various mechanisms that enhance or inhibit adrenergic signaling. Adrenergic neurotransmission refers to the release of norepinephrine (NE) and epinephrine (Epi) from adrenergic nerve endings, which then interact with adrenergic receptors (alpha and beta receptors) on target tissues. This complex process plays a crucial role in regulating various physiological functions such as heart rate, blood pressure, and smooth muscle tone.

Mechanisms of Adrenergic Modulation

1. 1. Synthesis of Catecholamines

• Tyrosine Hydroxylase Inhibitors: Drugs like alpha-methyltyrosine inhibit tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of catecholamines. By reducing the production of norepinephrine and epinephrine, these drugs decrease adrenergic signaling, which can be useful in managing conditions like pheochromocytoma (a tumor of the adrenal glands that produces excessive catecholamines) and hypertension.

1. 2. Storage of Catecholamines

• Vesicular Monoamine Transporter (VMAT) Inhibitors: Reserpine inhibits VMAT, which transports norepinephrine into synaptic vesicles for storage. This depletion of norepinephrine stores leads to a reduction in adrenergic signaling. Reserpine has been historically used to treat hypertension and psychosis but is less commonly used today due to its side effect profile.

1. 3. Release of Catecholamines

• Presynaptic Alpha-2 Agonists: Drugs like clonidine and other alpha-2 adrenergic agonists activate presynaptic alpha-2 receptors, which inhibit the release of norepinephrine through negative feedback mechanisms. These agents are primarily used in the treatment of hypertension, ADHD, and withdrawal symptoms from opioids. They act by reducing sympathetic outflow.
• Indirect Sympathomimetics: Amphetamines and related compounds promote the release of norepinephrine from presynaptic nerve terminals by reversing the norepinephrine transporter (NET) and displacing norepinephrine from storage vesicles. These drugs have stimulant effects and are used in the treatment of ADHD and narcolepsy, but their abuse potential is high.

1. 4. Reuptake of Catecholamines

• Norepinephrine Transporter (NET) Inhibitors: Cocaine and tricyclic antidepressants (TCAs), such as amitriptyline, block the reuptake of norepinephrine into presynaptic neurons by inhibiting NET. This leads to increased levels of norepinephrine in the synaptic cleft, enhancing adrenergic signaling. Cocaine’s action as a NET inhibitor contributes to its addictive properties and sympathomimetic effects, including increased heart rate and blood pressure.

1. 5. Metabolism of Catecholamines

• Monoamine Oxidase Inhibitors (MAOIs): Drugs such as phenelzine and tranylcypromine inhibit monoamine oxidase (MAO), an enzyme responsible for the breakdown of norepinephrine, serotonin, and dopamine. By preventing the metabolism of norepinephrine, MAOIs increase its levels and are used in the treatment of depression, although they have a risk of hypertensive crises when taken with foods containing tyramine.